These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 14571743)

  • 1. Effects of propionyl-L-carnitine topical irrigation in distal ulcerative colitis: a preliminary report.
    Gasbarrini G; Mingrone G; Giancaterini A; De Gaetano A; Scarfone A; Capristo E; Calvani M; Caso V; Greco AV
    Hepatogastroenterology; 2003; 50(53):1385-9. PubMed ID: 14571743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of propyonil-l-carnitine topical irrigation in distal ulcerative colitis: a preliminary report.
    Giancaterini A; Mingrone G; De Gaetano A; Capristo E; Calvani M; Caso V; Greco AV; Gasbarrini G
    Am J Gastroenterol; 2001 Jul; 96(7):2275-6. PubMed ID: 11467678
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment.
    Mikhailova TL; Sishkova E; Poniewierka E; Zhidkov KP; Bakulin IG; Kupcinskas L; Lesniakowski K; Grinevich VB; Malecka-Panas E; Ardizzone S; D'Arienzo A; Valpiani D; Koch M; Denapiene G; Vago G; Fociani P; Zerbi P; Ceracchi M; Camerini R; Gasbarrini G
    Aliment Pharmacol Ther; 2011 Nov; 34(9):1088-97. PubMed ID: 21929562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab.
    Hassan C; Ierardi E; Burattini O; De Francesco V; Zullo A; Stoppino G; Panella C; Morini S
    Dig Liver Dis; 2007 Sep; 39(9):811-7. PubMed ID: 17652038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review.
    Ferrari R; Merli E; Cicchitelli G; Mele D; Fucili A; Ceconi C
    Ann N Y Acad Sci; 2004 Nov; 1033():79-91. PubMed ID: 15591005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
    Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
    Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: a pilot study.
    Federico A; Tuccillo C; Grossi E; Abbiati R; Garbagna N; Romano M; Tiso A; Blanco Cdel V; Loguercio C
    Eur Rev Med Pharmacol Sci; 2009; 13(4):285-93. PubMed ID: 19694343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
    Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
    Eliakim R; Tulassay Z; Kupcinskas L; Adamonis K; Pokrotnieks J; Bar-Meir S; Lavy A; Mueller R; Greinwald R; Chermesh I; Gross V;
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1237-49. PubMed ID: 17944738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal features and granulocyte-monocyte-apheresis in steroid-dependent/refractory ulcerative colitis.
    D'Ovidio V; Aratari A; Viscido A; Marcheggiano A; Papi C; Capurso L; Caprilli R
    Dig Liver Dis; 2006 Jun; 38(6):389-94. PubMed ID: 16569521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan.
    Hibi T; Sameshima Y; Sekiguchi Y; Hisatome Y; Maruyama F; Moriwaki K; Shima C; Saniabadi AR; Matsumoto T
    Dig Liver Dis; 2009 Aug; 41(8):570-7. PubMed ID: 19211314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging.
    Cavallini G; Caracciolo S; Vitali G; Modenini F; Biagiotti G
    Urology; 2004 Apr; 63(4):641-6. PubMed ID: 15072869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of olsalazine (dipentum) in the treatment of patients with ulcerative colitis--results of a field study.
    Singer MV; Schmausser H; Schönfeld G
    Hepatogastroenterology; 2006; 53(69):317-21. PubMed ID: 16795963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial.
    Dal Lago A; De Martini D; Flore R; Gaetani E; Gasbarrini A; Gerardino L; Pola R; Santoliquido A; Serricchio M; Tondi P; Nolfe G
    Drugs Exp Clin Res; 1999; 25(1):29-36. PubMed ID: 10337502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis.
    Mawdsley JE; Macey MG; Feakins RM; Langmead L; Rampton DS
    Gastroenterology; 2006 Aug; 131(2):410-9. PubMed ID: 16890594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis.
    Olsen T; Goll R; Cui G; Husebekk A; Vonen B; Birketvedt GS; Florholmen J
    Scand J Gastroenterol; 2007 Nov; 42(11):1312-20. PubMed ID: 17852866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II.
    Riccioni C; Sarcinella R; Palermo G; Izzo A; Liguori M; Koverech A; Messano M; Virmani A
    Int Angiol; 2008 Jun; 27(3):253-9. PubMed ID: 18506129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
    D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.